How MajorGlow Decides Whether a New Treatment Belongs on the Menu

AESTHETIC EDUCATION

Aesthetic medicine moves quickly. New devices, injectables and regenerative treatments appear constantly, often surrounded by dramatic before-and-after images and early enthusiasm. MajorGlow does not want a menu built around novelty. A new treatment should earn its place by solving a real problem better, more safely or more appropriately than what is already available.

Start with the problem the treatment is supposed to solve

The first question is not whether a treatment is trending. It is what concern it addresses, which patients it may help and whether the expected improvement is meaningful enough to justify another option on the menu.

Look at evidence separately from marketing

Manufacturer materials can explain how a product or device is intended to work, but they are not the same as independent evidence or long-term clinical experience. Claims need to be weighed against the quality of the data and the limits of what has actually been studied.

Safety and reversibility matter

A treatment with a modest benefit may not make sense if the complication profile, recovery or uncertainty is disproportionate. We also consider what can be done if the result is unsatisfactory and whether complications can be recognized and managed appropriately.

Ask whether we already have a better tool

Adding another device or injectable does not help patients if it duplicates a treatment that already works well. A new option should fill a real gap, improve candidacy for certain patients or offer a meaningful difference in recovery, precision or outcome.

Training and technique are part of the decision

A device or product does not create a good result on its own. We consider the training required, the experience needed to use it safely and whether the treatment can be delivered consistently within the practice.

Consider the full patient experience

Cost, number of sessions, downtime, maintenance and how easily the treatment fits into a broader plan all affect whether patients will actually find it useful.

The menu should stay intentional

MajorGlow would rather have fewer treatments with clear roles than a long list of options that overlap. New treatments should make the treatment plan simpler or better—not just make the menu longer.